Andrews MG, Mukhtar T, Eze UC, Simoneau CR, Perez Y, Mostajo-Radji MA, Wang S, Velmeshev D, Salma J, Kumar GR, Pollen AA, Crouch EE, Ott M, Kriegstein AR.
doi: 10.1101/2021.01.17.427024.
Publication Category: COVID-19 (SARS-CoV-2)
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2.
Chen I, Longbotham J.E, McMahon S, Suryawanshi R, Carlson-Stevermer J, Gupta M, Zhang MY, Soveg F.W , Hayashi J.M , Taha T.H, Lam V.L, Li Y, Yu Z, Titus E.W, Diallo A, Oki J, Holden K, QCRG Structural Biology Consortium; Krogan N, Fujimori D, Ott MViral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2. Cell Rep. 2022. doi: 10.1016/j.celrep.2022.111088. Epub 2022 Jun 27
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M. Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination. Nature. 2022. doi: 10.1038/s41586-022-04865-0.
Neutralizing antibody activity against SARS-CoV-2 variants in gestational age–matched mother-infant dyads after infection or vaccination.
Matsui Y, Li L, Prahl M, Cassidy A, Ozarslan N, Golan Y, Gonzalez V, Lin C, Jigmeddagva U, Chidboy M, Montano M, Taha T, Khalid M, Sreekumar B, Hayashi J, Chen P, Kumar G, Warrier L, Wu A, Song D, Jegatheesan P, Rai D, Govindaswami B, Needens J, Rincon M, Myatt L, Asiodu I, Flaherman V, Afshar Y, Jacoby V, Murtha A, Robinson J, Ott M, Greene W, Gaw S. Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. JCI Insight. 2022 . doi: 10.1172/jci.insight.157354.
A single-component luminescent biosensor for the SARS-CoV-2 spike protein.
Ravalin M, Roh H, Suryawanshi R, Kumar GR, Pak J, Ott M, Ting AY.
bioRxiv [Preprint]. 2022 Jun 15:2022.06.15.496006. doi: 10.1101/2022.06.15.496006. Update in: J Am Chem Soc. 2022 Aug 3;144(30):13663-13672. PMID: 35734091; PMCID: PMC9216720.
Immediate myeloid depot for SARS-CoV-2 in the human lung.
Magnen M, You R, Rao AA, Davis RT, Rodriguez L, Simoneau CR, Hysenaj L, Hu KH; UCSF COMET Consortium; Love C, Woodruff PG, Erle DJ, Hendrickson CM, Calfee CS, Matthay MA, Roose JP, Sil A, Ott M, Langelier CR, Krummel MF, Looney MR.
Res Sq [Preprint]. 2022 May 17:rs.3.rs-1639631. doi: 10.21203/rs.3.rs-1639631/v1. PMID: 35611333; PMCID: PMC9128787.
Novel RT-ddPCR assays for measuring the levels of subgenomic and genomic SARS-CoV-2 transcripts.
Telwatte S, Martin HA, Marczak R, Fozouni P, Vallejo-Gracia A, Kumar GR, Murray V, Lee S, Ott M, Wong JK, Yukl SA.
doi: 10.1016/j.ymeth.2021.04.011.
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, Sreekumar B, Khalid MM, Ciling A, Chen PY, Kumar GR, Gliwa AS, Nguyen J, Sotomayor-Gonzalez A, Zhang Y, Frias E, Prostko J, Hackett J Jr, Andino R, Wadford DA, Hanson C*, Doudna J,* Ott M*, Chiu CY*. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022. doi: 10.1016/j.cell.2022.03.019.
Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles.
Syed AM, Taha TY, Tabata T, Chen IP, Ciling A, Khalid MM, Sreekumar B, Chen P-Y, Hayashi JM, Soczek KM, Ott M, Doudna JA. Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles. Science.0(0):eabl6184. doi: doi:10.1126/science.abl6184.
Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A, Tanner E, Illouz S, Rahgoshay D, Burnett J, Holguin L, Chen PY, Ndjamen B, Ott M, Rodick R, Rogers T, Smith DM, Weinberger LS. Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. Cell. 2021 Dec 9;184(25):6022-6036.e18. doi: 10.1016/j.cell.2021.11.004. Epub 2021 Nov 10. PMID: 34838159; PMCID: PMC8577993.